57 results
DEF 14A
EX-99
RGEN
Repligen Corp.
22 Aug 95
Definitive proxy
12:00am
1995 was a difficult year for
biotechnology companies. Structural changes in the pharmaceutical industry and
healthcare environment, coupled … with a scarcity of new capital, motivated us to
review the business strategy outlined in last year's annual report. The current
business environment combined
8-K
EX-99
RGEN
Repligen Corp.
2 Jan 98
Current report
12:00am
; and the competitive environment
of the biotechnology and pharmaceutical industries. These factors are more fully
discussed in the Company's periodic filings with the Securities and Exchange
Commission.
####
8-K
EX-99.1
RGEN
Repligen Corp.
19 May 00
Current report
12:00am
protection to the Company, the risks of technological change and competition,
and the competitive environment of the biotechnology and pharmaceutical
8-K
EX-99.1
RGEN
Repligen Corp.
5 Aug 10
Vice President, Market Development
12:00am
2011 Financial Results, August 5, 2010
Page 3 of 4
environment; however, this quarter we experienced significant growth in our product revenue due
8-K
EX-99.1
RGEN
Repligen Corp.
9 Jun 10
Vice President, Market Development
12:00am
licensing agreement and the decrease in product revenue was primarily due to lower customer demand caused by the economic environment.
Operating expenses
8-K
EX-99.1
zx6cg
6 May 20
Repligen Reports First Quarter 2020 Financial Results
7:51am
8-K
EX-99.1
plerls
2 May 23
Repligen Reports First Quarter 2023 Financial Results
7:48am
DEFR14A
sovupoe89ttdvg29jo
5 May 21
Revised proxy
4:16pm
8-K
EX-99.1
av8rpf3l6pumyh
31 Oct 23
Repligen Reports Third Quarter 2023 Financial Results
7:48am
8-K
EX-2.1
1qt2j34vhrf6
28 Oct 11
Entry into a Material Definitive Agreement
12:00am